Jeremy Ryan

26PUBLICATIONS
159CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyHaematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|May 26, 2026
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

|Dec 26, 2025
Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Maria Davern, Cole J Turner, Daryl Griffin

|Dec 05, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

|Nov 15, 2024
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.

Marlise R Luskin, Shai Shimony, Julia Keating

|Mar 05, 2024
Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.

Elyse A Olesinski, Karanpreet Singh Bhatia, Chuqi Wang

|Jan 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

Pageof 5

Frequent Collaborators

14 joint publications

Anthony Letai

6 joint publications

Jacqueline S Garcia

5 joint publications

Daniel J DeAngelo

3 joint publications

Marlise R Luskin